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Cattle	 Nigeria	 Yes	 50	days	 [69,70]	




























Congo	Belge	 Yes	 15	days	 [43]	
Patas	monkey	(Erythrocebus	patas	
patas)	













Bay	duiker	(Cephalopus	dorsalis)	 Belgian	Congo	 Yes	 24	months	 [44]	
Waterbuck	(Kobus	ellipsiprymnus)		 Uganda		 Not	tested	 	 [46]	
Reedbuck	(Redunca	redunca)	 Uganda	 Yes	 15	months	 [46]	
Bushbuck	(Tragelaphus	spekei)	 Uganda	 Yes	 22	months	 [46]	
Rodents	
Gambian	pouched	rat	(Cricetomys	
gambianus)	
République	populaire	du	
Congo	
Yes	 154	days	 [33,76,77]	
Thicket	rat	(Thamnomys	rutilans),	
Jackson's	praomys	(Praomys	
jacksoni),	African	marsh	rat	(Dasymys	
République	populaire	du	
Congo	
Not	tested	 131	days	 [76]	
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incomtus),	Striped	grass	mouse	
(Lemniscomus	striatus),	Rusty-nosed	
rat	(Cenomys	hypoxanthus),	African	
brush-tailed	porcupine	(Atherurus	
africanus)	
a For	reasons	of	traceability,	we	use	the	name	of	countries	and	the	scientific	name	of	animals	as	mentioned	in	the	original	publication:	Senegambia	=	Senegal	and	493 
The	Gambia;	Belgian	Congo,	Congo	Free	State	and	Congo	Belge	=	Democratic	Republic	of	the	Congo;	République	populaire	du	Congo	=	Republic	of	the	Congo. 494 
 495 
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Box	1:		 Diversity	in	outcomes	of	human	Trypanosoma	brucei	gambiense	infections	496 
There	is	growing	evidence	that	infection	with	T.b.	gambiense	does	not	always	follow	the	497 
classical	course	of	the	disease,	i.e.	a	first	haemo-lymphatic	stage	followed	by	a	second	stage	498 
with	central	nervous	system	involvement	progressing	to	death	if	left	untreated	(see	Figure	499 
I).	These	symptomatic	HAT	patients	are	characterised	by	the	detection	of	parasites	in	any	500 
body	fluid	(P+),	detection	of	specific	antibodies	against	T.b.	gambiense	Variable	Antigen	501 
Type	LiTat	1.3	or	LiTat	1.5	in	immune	trypanolysis	(TL+),	and	the	presence	of	clinical	502 
symptoms.	However,	long-term	follow-up	studies	in	West	Africa	have	shown	that	a	number	503 
of	infected	individuals	do	not	develop	the	disease	and	can	be	classified	as	having	latent	504 
infections	(i.e.	they	are	healthy	carriers)	[7].	They	remain	asymptomatic	without	detectable	505 
parasites	(P-)	for	several	years,	although	they	are	consistently	positive	in	the	immune	506 
trypanolysis	test	(TL+).	Moreover,	some	of	them	may	become	immune	trypanolysis	negative	507 
(TL-)	over	time	suggesting	that	they	self-cured	and	therefore	cannot	transmit	the	parasite	508 
anymore.	509 
	 	510 
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	511 
	512 
Figure	1:	Trypanosoma	brucei	gambiense	in	non-human	mammals.	Map	showing	513 
gambiense-human	African	trypanosomiasis	in	endemic	countries	and	sites	where	T.	b.	514 
gambiense	infection	in	non-human	mammals	has	been	investigated	with	direct	and	indirect	515 
methods.	Circles	represent	direct	or	indirect	evidence	of	presence	(red)	and	of	absence	516 
(green)	of	T.b.	gambiense	in	the	period	1990-2016.	For	this	period,	data	are	mapped	at	the	517 
village/site	level.	(Blue)	stars	represent	presence	of	detection	in	the	years	prior	to	1990.	For	518 
this	period,	data	are	mapped	at	the	country	level.	All	source	references	are	provided	as	519 
Supplemental	Information.	520 
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	521 
Figure	2,	Key	Figure:		Unknown	elements	in	human	African	trypanosomiasis	progression	522 
and	transmission.	Solid	lines	represent	progression	between	disease	states,	and	dashed	523 
lines	represent	transmission	of	the	parasites	to	and	from	the	tsetse	vector.	Red	boxes	524 
denote	people	or	animals	that	may	be	infective	to	tsetse,	with	the	darker	shades	denoting	525 
possible	greater	infectiveness.	The	figure	highlights	key	unknown	elements	in	disease	526 
progression	and	transmission	including:	(1)	the	probability	of	an	infection	leading	to	latent	527 
or	stage	1	disease	in	humans;	if,	and	how	frequently,	(2)	self-cure	of	infected	humans	or	(3)	528 
animals	arises,	(4)	the	duration	of	latent	infection	in	humans	or	(5)	any	infections	in	animals,	529 
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and	(6)	the	relative	probability	of	transmission	to	tsetse	from	different	types	of	infections	530 
(accounting	for	host	feeding	preferences).	531 
	532 
	533 
Figure	I	(Box	1):	Outcomes	of	human	infection	with	Trypanosoma	brucei	gambiense.	534 
When	naïve	persons	(Uninfected),	without	specific	antibodies	(TL-)	and	without	parasites	(P-535 
)	get	infected	with	T.b.	gambiense,	they	undergo	an	early	phase	of	the	disease	with	536 
detectable	parasitaemia	(P+)	but	without	detectable	specific	antibodies.	Thereafter,	most	of	537 
them	develop	the	disease	(HAT	patient)	and	are	characterised	by	specific	antibodies	(TL+)	538 
and	detectable	parasitaemia	(P+).	Some	remain	asymptomatic	(Latent	infection)	with	539 
detectable	specific	antibodies	but	without	detectable	parasites	(TL+,	P-).	Evidence	for	self-540 
cure	comes	from	asymptomatic	people	that	also	eventually	become	negative	for	specific	541 
antibodies	(TL-,	P-).	542 
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Glossary	545 
Anthroponotic	disease:	an	infectious	disease	typically	transmitted	from	human	to	human	546 
(including	through	an	insect	vector).		547 
Blood	Incubation	Infectivity	Test:	T.b.	gambiense	and	T.b.	rhodesiense	have	developed	548 
mechanisms	to	withstand	lysis	by	normal	human	serum,	in	contrast	with	animal	infective	549 
trypanosomes	like	T.b.	brucei,	T.	congolense,	T.	vivax.	To	confirm	that	an	animal	is	infected	550 
with	T.b.	gambiense	or	T.b.	rhodesiense,	its	blood,	or	trypanosomes	isolated	from	that	551 
animal,	are	incubated	with	human	blood	or	serum	where	after	this	mixture	is	injected	in	a	552 
susceptible	animal.	Only	human	serum	resistant	trypanosomes	will	be	able	to	initiate	an	553 
infection	in	the	susceptible	animal.	554 
CATT/T.b.gambiense:	Card	Agglutination	Test	for	Trypanosomiasis	is	an	agglutination	test	555 
for	detection	of	gambiense-specific	antibodies	in	blood.	It	was	the	first	field-applicable	556 
serological	test	introduced	in	the	1980s	for	large-scale	screening	of	populations	at	risk	for	557 
gambiense-HAT.	558 
Deterministic	mathematical	model:	Deterministic	models	ignore	the	impact	of	random	559 
events,	instead	capturing	average	disease	dynamics,	so	that	multiple	simulations	with	the	560 
same	parameter	values	and	initial	conditions	will	lead	to	exactly	the	same	outcome.		561 
Elimination	of	gambiense-HAT:	Elimination	is	the	reduction	to	zero	of	gambiense-HAT	562 
incidence	in	a	defined	area	as	a	result	of	deliberate	efforts;	measures	to	prevent	re-563 
emergence	are	required.		564 
Elimination	of	gambiense-HAT	as	a	public	health	problem:	90%	reduction	in	areas	565 
reporting	more	than	1	case	in	10,000	compared	to	2000-2004,	and	fewer	than	2,000	566 
annually	reported	cases	globally.	567 
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Eradication	of	gambiense-HAT:	Eradication	is	the	permanent	reduction	to	zero	of	the	568 
worldwide	incidence	of	gambiense-HAT	as	a	result	of	deliberate	efforts;	intervention	569 
measures	are	no	longer	needed.	570 
HAT	focus:	A	geographically	defined	zone	where	transmission	of	HAT	occurs	or	has	571 
occurred,	to	which	a	geographical	name	is	given	(locality,	region	and	river).	572 
Immune	trypanolysis:	Highly	accurate	test	for	gambiense-specific	antibodies,	based	on	573 
antibody-mediated	complement	lysis	of	trypanosomes	exposing	one	single	variant-specific	574 
antigen	on	their	surface.	575 
Latent	infection:	On-going	infection	not	progressing	to	clinical	disease,	that	may	remain	576 
undiagnosed.	577 
Maintenance	community:	One	or	more	populations	which	can	transmit	the	pathogen	and,	578 
together,	can	maintain	the	pathogen		579 
Maintenance	population:	Individual	populations	which	can	transmit	the	pathogen	and	can	580 
also	maintain	the	pathogen	in	the	absence	of	other	reservoir	populations.	581 
Rapid	diagnostic	test	(RDT):	Serological	antibody	or	antigen	detection	test,	conditioned	as	582 
individual	test,	compliant	with	the	ASSURED	criteria	(Affordable,	Sensitive,	Specific,	User-583 
friendly,	Rapid	and	robust,	Equipment-free	and	Deliverable	to	end-users);	RDTs	for	584 
gambiense-HAT	detect	antibodies	against	predominant	gambiense-specific	antigens.	585 
Reservoir:	Host	where	the	pathogen	can	maintain	itself	and	from	where	it	can	be	586 
transmitted	to	another	host;	a	reservoir	host	is	essential	to	sustain	infection.	587 
Self-cure:	Infection	that	is	cleared	by	the	host	without	treatment.	588 
Specificity:	The	specificity	of	a	diagnostic	test	is	the	probability	that	the	test	result	is	589 
negative	when	the	test	person	is	not	infected.	It	is	usually	expressed	as	percentage	and	590 
calculated	by	dividing	the	number	of	test	negatives	by	the	number	of	true	negatives	x	100.	591 
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Stage	determination:	HAT	develops	from	an	early	stage	with	parasites	in	the	peripheral	592 
tissues	towards	a	late	stage	with	parasite	invasion	into	the	central	nervous	system.	593 
Treatment	is	different	for	both	stages,	thus	requiring	stage	determination	before	drug	594 
administration.	Determination	of	the	stage	is	achieved	by	examination	of	the	cerebrospinal	595 
fluid	for	the	presence	of	trypanosomes	and	the	number	of	white	blood	cells.	596 
Stochastic	mathematical	model:	Stochastic	models	include	chance	events	so	that	two	597 
simulations	with	the	same	parameter	values	and	initial	conditions	may	lead	to	different	598 
outcomes.	Chance	events	become	more	important	at	very	low	prevalences	such	as	in	pre-599 
elimination	or	re-emergent	settings.	600 
Variant	Surface	Glycoprotein	(VSG):	In	the	vertebrate	host,	the	cell	surface	of	601 
trypanosomes	is	covered	with	a	layer	of	identical	VSGs	of	one	particular	variant	antigen	type	602 
(VAT),	that	protects	the	trypanosomes	against	innate	immune	defence	mechanisms	of	the	603 
host;	VSGs	are	highly	immunogenic	but	periodic	switches	of	the	VAT	of	the	VSG	coat	604 
(antigenic	variation)	enable	the	trypanosome	to	escape	the	host	humoral	immune	response;	605 
during	the	course	of	the	infection,	the	host	blood	contains	antibodies	against	a	wide	606 
spectrum	of	different	VATs.	607 
Xenodiagnosis:	Diagnostic	method	based	on	detection	of	the	parasite	in	susceptible	vectors	608 
after	they	were	fed	on	an	individual	suspected	of	being	infected	with	the	parasite;	in	HAT,	609 
the	vectors	used	are	teneral	tsetse	flies.	610 
	611 
	612 
